Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 10, 2023

SELL
$283.23 - $323.1 $160,024 - $182,551
-565 Reduced 28.97%
1,385 $436,000
Q4 2022

Feb 13, 2023

BUY
$285.76 - $321.48 $11,430 - $12,859
40 Added 2.09%
1,950 $563,000
Q3 2022

Nov 10, 2022

SELL
$273.83 - $305.53 $13,691 - $15,276
-50 Reduced 2.55%
1,910 $552,000
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $46,992 - $58,510
-200 Reduced 9.26%
1,960 $553,000
Q1 2022

Apr 28, 2022

BUY
$221.42 - $260.97 $11,071 - $13,048
50 Added 2.37%
2,160 $564,000
Q4 2021

Feb 07, 2022

BUY
$177.01 - $223.45 $6,195 - $7,820
35 Added 1.69%
2,110 $463,000
Q2 2021

Jul 29, 2021

BUY
$187.49 - $221.1 $11,249 - $13,266
60 Added 2.98%
2,075 $419,000
Q1 2021

Apr 22, 2021

BUY
$207.02 - $241.31 $10,351 - $12,065
50 Added 2.54%
2,015 $433,000
Q2 2020

Aug 11, 2020

SELL
$225.48 - $295.8 $107,103 - $140,505
-475 Reduced 19.47%
1,965 $570,000
Q4 2019

Feb 12, 2020

SELL
$166.71 - $223.91 $43,344 - $58,216
-260 Reduced 9.63%
2,440 $535,000
Q3 2019

Nov 13, 2019

SELL
$166.23 - $187.09 $16,623 - $18,709
-100 Reduced 3.57%
2,700 $458,000
Q1 2019

May 13, 2019

BUY
$163.73 - $194.7 $58,942 - $70,092
360 Added 14.75%
2,800 $515,000
Q4 2018

Feb 12, 2019

SELL
$151.91 - $192.21 $56,206 - $71,117
-370 Reduced 13.17%
2,440 $405,000
Q2 2018

Aug 13, 2018

SELL
$145.72 - $169.96 $1,457 - $1,699
-10 Reduced 0.35%
2,810 $477,000
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $15,160 - $17,713
-100 Reduced 3.42%
2,820 $460,000
Q4 2017

Feb 13, 2018

BUY
$137.28 - $155.55 $13,728 - $15,555
100 Added 3.55%
2,920 $438,000
Q3 2017

Nov 13, 2017

BUY
$148.13 - $162.24 $62,214 - $68,140
420 Added 17.5%
2,820 $429,000
Q2 2017

Aug 14, 2017

BUY
N/A
2,400
2,400 $309,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Hillsdale Investment Management Inc. Portfolio

Follow Hillsdale Investment Management Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Hillsdale Investment Management Inc., based on Form 13F filings with the SEC.

News

Stay updated on Hillsdale Investment Management Inc. with notifications on news.